

Date: November 9–10, 2020.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Jonathan Arias, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5170, MSC 7840 Bethesda, MD 20892, 301–435–2406, ariasj@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Health Services Organization and Delivery.

Date: November 9, 2020.

Time: 12:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Lauren Fordyce, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3214, Bethesda, MD 20892, (301) 827–8269, fordycelm@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: October 6, 2020.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–22523 Filed 10–9–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special

Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01).

Date: November 4, 2020.

Time: 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G42B, Rockville, MD 20892 (Virtual Meeting).

Contact Person: Louis A. Rosenthal, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Room 3G42B, Bethesda, MD 20892–9834, (240) 669–5070, rosenthalla@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: October 6, 2020.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–22524 Filed 10–9–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Novel and Exceptional Technology and Research Advisory Committee.

The meeting will be held as a virtual meeting and is open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov/>).

Name of Committee: Novel and Exceptional Technology and Research Advisory Committee.

Date: November 9, 2020.

Time: 10:00 a.m. to 5:15 p.m.

Agenda: The Novel and Exceptional Technology and Research Advisory Committee (NEXTRAC) will include a workshop to examine existing biosafety guidance for contained gene drive research and to discuss potential conditions under which NIH could consider supporting field release of gene drive-modified organisms.

Place: National Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892, (Virtual Meeting—Link for the

meeting will be available at <https://osp.od.nih.gov/biotechnology/main-nextrac/#meetings>).

Name of Committee: Novel and Exceptional Technology and Research Advisory Committee.

Date: November 10, 2020.

Time: 10:00 a.m. to 5:15 p.m.

Agenda: The Novel and Exceptional Technology and Research Advisory Committee (NEXTRAC) will include (1) a workshop to examine existing biosafety guidance for contained gene drive research and to discuss potential conditions under which NIH could consider supporting field release of gene drive-modified organisms, and (2) discussion of a draft report conceptualizing a framework for NEXTRAC deliberation of issues surrounding emerging biotechnologies.

Place: National Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892, (Virtual Meeting—Link for the meeting will be available at <https://osp.od.nih.gov/biotechnology/main-nextrac/#meetings>).

Contact Person: Kinshasa Letts, Office of Science Policy, National Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892, 301–496–9838, SciencePolicy@od.nih.gov.

To sign up to make an oral public comment, please submit your name, affiliation, and short description of the oral comment to the Contact Person listed above by 5:00 p.m. EST, November 3, 2020. Sign up will be restricted to one sign up per email and oral comments will be limited to two minutes. Once all time slots are filled, only written comments will be accepted. Any interested person may file written comments by forwarding their statement to the Contact Person listed on this notice. The Contact Person should receive any written statements by 5:00 p.m. EST, November 5, 2020.

Information is also available on the NEXTRAC web page: <https://osp.od.nih.gov/biotechnology/main-nextrac/#meetings>, where an agenda and any additional information for the meeting will be posted when available. The Draft Report of the Working Group to Establish a NEXTRAC Framework will be posted prior to the meeting. Please check this website for updates.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: October 7, 2020.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–22600 Filed 10–9–20; 8:45 am]

BILLING CODE 4140–01–P